Adverse Effects of Aldosterone: Beyond Blood Pressure

被引:3
|
作者
Brown, Jenifer M. [1 ,2 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA USA
[2] Brigham & Womens Hosp, 75 Francis Str, Boston, MA 02115 USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2024年 / 13卷 / 07期
基金
美国国家卫生研究院;
关键词
aldosterone; heart failure; hyperaldosteronism; hypertension; mineralocorticoid receptor; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE EFFICACY; CHRONIC KIDNEY-DISEASE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MILD PATIENTS HOSPITALIZATION; LEFT-VENTRICULAR HYPERTROPHY; FINERENONE VS. EPLERENONE; TO-RENIN RATIO; ESSENTIAL-HYPERTENSION; CARDIOVASCULAR EVENTS;
D O I
10.1161/JAHA.123.030142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aldosterone is a steroid hormone that primarily acts through activation of the mineralocorticoid receptor (MR), a nuclear receptor responsible for downstream genomic regulation. Classically, activation of the MR in the renal tubular epithelium is responsible for sodium retention and volume expansion, raising systemic blood pressure. However, activation of the MR across a wide distribution of tissue types has been implicated in multiple adverse consequences for cardiovascular, cerebrovascular, renal, and metabolic disease, independent of blood pressure alone. Primary aldosteronism, heart failure, and chronic kidney disease are states of excessive aldosterone production and MR activity where targeting MR activation has had clinical benefits out of proportion to blood pressure lowering. The growing list of established and emerging therapies that target aldosterone and MR activation may provide new opportunities to improve clinical outcomes and enhance cardiovascular and renal health.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Blood Aldosterone-to-Renin Ratio, Ambulatory Blood Pressure, and Left Ventricular Mass in Children
    Li, Rongling
    Richey, Phyllis A.
    DiSessa, Thomas G.
    Alpert, Bruce S.
    Jones, Deborah P.
    JOURNAL OF PEDIATRICS, 2009, 155 (02) : 170 - 175
  • [32] Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia
    Chrysant, Steven G.
    Chrysant, George S.
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (01) : 59 - 67
  • [33] Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women
    Morgante, Giuseppe
    Delia, Ada
    Musacchio, Maria C.
    Severi, F. M.
    Petraglia, Felice
    De Leo, Vincenzo
    GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (07) : 376 - 380
  • [34] Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure - are they important for doctors?
    Holecki, Michal
    Szewieczek, Jan
    Chudek, Jerzy
    PHARMACOLOGICAL REPORTS, 2011, 63 (03) : 740 - 751
  • [35] Placebo-associated blood pressure response and adverse effects.
    Materson, BJ
    Preston, RA
    Reda, DJ
    Williams, D
    AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) : 42A - 42A
  • [36] BEYOND BLOOD-PRESSURE
    POULTER, NR
    JOURNAL OF HUMAN HYPERTENSION, 1994, 8 : S3 - S8
  • [37] Resistant hypertension: beyond a bad control of blood pressure
    Camafort, Miguel
    Coca, Antonio
    MEDICINA CLINICA, 2011, 137 (10): : 444 - 445
  • [38] Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo
    Queisser, Nina
    Amann, Kerstin
    Hey, Valentin
    Habib, Samy L.
    Schupp, Nicole
    FREE RADICAL BIOLOGY AND MEDICINE, 2013, 54 : 17 - 25
  • [39] Are There Benefits of Antihypertensive Therapy Beyond Blood Pressure Lowering?
    Izzo, Joseph L., Jr.
    CURRENT HYPERTENSION REPORTS, 2010, 12 (06) : 440 - 447
  • [40] Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients
    Aoki, Akiko
    Ogawa, Tetsuya
    Sumino, Hiroyuki
    Kumakura, Hisao
    Takayama, Yoshiaki
    Ichikawa, Shuichi
    Nitta, Kosaku
    HEART AND VESSELS, 2010, 25 (03) : 195 - 202